Kyriakos Amarantidis

513 total citations
29 papers, 405 citations indexed

About

Kyriakos Amarantidis is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kyriakos Amarantidis has authored 29 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kyriakos Amarantidis's work include Colorectal Cancer Treatments and Studies (13 papers), Cancer Treatment and Pharmacology (8 papers) and Epigenetics and DNA Methylation (7 papers). Kyriakos Amarantidis is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Cancer Treatment and Pharmacology (8 papers) and Epigenetics and DNA Methylation (7 papers). Kyriakos Amarantidis collaborates with scholars based in Greece, United States and Cyprus. Kyriakos Amarantidis's co-authors include Stylianos Kakolyris, Nikolaos Xenidis, Anastasios J. Karayiannakis, Leonidas Chelis, Ioanna Balgkouranidou, Εkaterini Chatzaki, Grigorios Trypsianis, Evi Lianidou, Helen Bolanaki and Dimitrios Matthaios and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Molecular Sciences.

In The Last Decade

Kyriakos Amarantidis

28 papers receiving 401 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kyriakos Amarantidis Greece 10 160 141 141 75 54 29 405
Marcia Mulquin United States 8 112 0.7× 161 1.1× 48 0.3× 61 0.8× 26 0.5× 19 308
Claudia Gedlicka Austria 12 244 1.5× 157 1.1× 48 0.3× 91 1.2× 18 0.3× 16 383
Helen Ye United States 5 73 0.5× 209 1.5× 45 0.3× 95 1.3× 11 0.2× 7 346
Duan‐Bo Shi China 15 98 0.6× 443 3.1× 358 2.5× 68 0.9× 13 0.2× 28 582
Marie-Hélène Louis France 12 76 0.5× 261 1.9× 156 1.1× 42 0.6× 8 0.1× 19 388
Rhyannon Spangler United States 4 107 0.7× 175 1.2× 122 0.9× 69 0.9× 7 0.1× 4 340
Chuang Lin China 9 90 0.6× 272 1.9× 162 1.1× 52 0.7× 9 0.2× 12 416
Diana Mendus United States 10 492 3.1× 46 0.3× 54 0.4× 375 5.0× 25 0.5× 15 587
Zhenzhen Fan China 10 104 0.7× 115 0.8× 46 0.3× 41 0.5× 6 0.1× 20 285

Countries citing papers authored by Kyriakos Amarantidis

Since Specialization
Citations

This map shows the geographic impact of Kyriakos Amarantidis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyriakos Amarantidis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyriakos Amarantidis more than expected).

Fields of papers citing papers by Kyriakos Amarantidis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyriakos Amarantidis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyriakos Amarantidis. The network helps show where Kyriakos Amarantidis may publish in the future.

Co-authorship network of co-authors of Kyriakos Amarantidis

This figure shows the co-authorship network connecting the top 25 collaborators of Kyriakos Amarantidis. A scholar is included among the top collaborators of Kyriakos Amarantidis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyriakos Amarantidis. Kyriakos Amarantidis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ragia, Georgia, et al.. (2024). MIR27A rs895819 TC Genotype Increases Risk of Fluoropyrimidine-Induced Severe Toxicity Independently of DPYD Variations. Pharmacogenomics. 25(2). 59–67. 2 indexed citations
2.
Παναγοπούλου, Μαρία, Makrina Karaglani, Konstantinos Arvanitidis, et al.. (2024). Mitochondrial Fraction of Circulating Cell-Free DNA as an Indicator of Human Pathology. International Journal of Molecular Sciences. 25(8). 4199–4199. 7 indexed citations
3.
Balgkouranidou, Ioanna, Eirini Biziota, Anastasios J. Karayiannakis, et al.. (2024). Prognostic significance of BRCA1 and BRCA2 methylation status in circulating cell-free DNA of Pancreatic Cancer patients. Journal of Cancer. 15(9). 2573–2579. 3 indexed citations
4.
Ragia, Georgia, Eirini Biziota, Ioanna Balgkouranidou, et al.. (2023). Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece. Frontiers in Pharmacology. 14. 1248898–1248898. 7 indexed citations
5.
Ragia, Georgia, Ioanna Balgkouranidou, Nikolaos Xenidis, et al.. (2022). MTHFR c.665C>T guided fluoropyrimidine therapy in cancer: gender-dependent effect on dose requirements. Drug Metabolism and Personalized Therapy. 37(3). 323–327. 7 indexed citations
6.
Ragia, Georgia, Ioanna Balgkouranidou, Nikolaos Xenidis, et al.. (2021). Gender-Dependent Association of Tyms -TSER Polymorphism With 5-Fluorouracil or Capecitabine-Based Chemotherapy Toxicity. Pharmacogenomics. 22(11). 669–680. 9 indexed citations
7.
Balgkouranidou, Ioanna, Nikolaos Xenidis, Kyriakos Amarantidis, et al.. (2021). Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients. Technology in Cancer Research & Treatment. 20. 1079240927–1079240927. 22 indexed citations
8.
Balgkouranidou, Ioanna, N. Xenidis, Kyriakos Amarantidis, et al.. (2019). Methylation status of RASSF1A associates with prognosis in metastatic gastric cancer. Gastroenterology & Hepatology Open Access. 10(6). 301–304. 1 indexed citations
9.
Karanikas, Michael, et al.. (2016). Pancreatic Cancer from Molecular Pathways to Treatment Opinion. Journal of Cancer. 7(10). 1328–1339. 28 indexed citations
10.
Matthaios, Dimitrios, Ioanna Balgkouranidou, Anastasios J. Karayiannakis, et al.. (2016). Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. Oncology Letters. 12(1). 748–756. 50 indexed citations
11.
Balgkouranidou, Ioanna, Dimitrios Matthaios, Anastasios J. Karayiannakis, et al.. (2015). Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 778. 46–51. 65 indexed citations
12.
Amarantidis, Kyriakos, Nikolaos Xenidis, Leonidas Chelis, et al.. (2011). Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer. Oncology. 80(5-6). 359–365. 18 indexed citations
13.
Xenidis, Nikolaos, Leonidas Chelis, Kyriakos Amarantidis, et al.. (2011). Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study. Cancer Chemotherapy and Pharmacology. 69(2). 477–484. 11 indexed citations
14.
Riga, Maria, Leonidas Chelis, Stylianos Kakolyris, et al.. (2011). Transtympanic Injections of N-acetylcysteine for the Prevention of Cisplatin-induced Ototoxicity. American Journal of Clinical Oncology. 36(1). 1–6. 83 indexed citations
15.
Xenidis, Nikolaos, et al.. (2010). Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer. Cancer Chemotherapy and Pharmacology. 67(1). 69–73. 3 indexed citations
16.
Amarantidis, Kyriakos, Nikolaos Xenidis, Leonidas Chelis, et al.. (2009). A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors. Acta Oncologica. 49(2). 245–251. 3 indexed citations
17.
Mantatzis, Michael, Stylianos Kakolyris, Kyriakos Amarantidis, Anastasios J. Karayiannakis, & Panos Prassopoulos. (2009). Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate?. European Radiology. 19(7). 1809–1816. 40 indexed citations
18.
19.
Maltezos, Efstratios, Kyriakos Amarantidis, Εkaterini Chatzaki, et al.. (2005). A Dose Escalation Study of Pegylated Liposomal Doxorubicin (Caelyx) in Combination with Capecitabine (Xeloda) in Patients with Refractory Solid Tumors. Oncology. 69(6). 463–469. 3 indexed citations
20.
Kakolyris, Stylianos, John Souglakos, Ch. Kouroussis, et al.. (2004). Dose Escalation Study on Oxaliplatin and Capecitabine (Xeloda) in Patients with Advanced Solid Tumors. Oncology. 66(4). 253–259. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marcia Mulquin Breakdown of academic impact, for papers by Claudia Gedlicka Breakdown of academic impact, for papers by Helen Ye Breakdown of academic impact, for papers by Duan‐Bo Shi Breakdown of academic impact, for papers by Marie-Hélène Louis Breakdown of academic impact, for papers by Rhyannon Spangler Breakdown of academic impact, for papers by Chuang Lin Breakdown of academic impact, for papers by Diana Mendus Breakdown of academic impact, for papers by Zhenzhen Fan
Rankless by CCL
2026